OverviewSuggest Edit

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
The Company's portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
TypePublic
Founded1987
HQFoster City, US
Websitegilead.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Jan 2019)11,000(+10%)
Job Openings485
Revenue (FY, 2018)$22.1 B(-15%)
Share Price (Mar 2019)$63.8 (-1%)

Key People/Management at Gilead Sciences

John F. Milligan

John F. Milligan

President and Chief Executive Officer
Gregg H. Alton

Gregg H. Alton

Chief Patient Officer
Andrew Dickinson

Andrew Dickinson

Executive Vice President, Corporate Development and Strategy
Laura Hamill

Laura Hamill

Executive Vice President, Worldwide Commercial Operations
William A. Lee

William A. Lee

Executive Vice President, Research
AO John McHutchison

AO John McHutchison

Chief Scientific Officer, Head of Research and Development
Show more

Gilead Sciences Office Locations

Gilead Sciences has offices in Foster City, Seattle, San Dimas, Oceanside and in 2 other locations
Foster City, US (HQ)
333 Lakeside Dr
Branford, US
36 E Industrial Rd
Fremont, US
7601 Dumbarton Cir
Oceanside, US
4049 Avenida De La Plata
San Dimas, US
650 Cliffside Dr
Seattle, US
199 E Blaine St
Show all (6)
Report incorrect company information

Gilead Sciences Financials and Metrics

Gilead Sciences Revenue

Embed Graph
View revenue for all periods
Gilead Sciences's revenue was reported to be $22.13 b in FY, 2018
USD

Revenue (FY, 2018)

22.1b

Gross profit (FY, 2018)

17.3b

Gross profit margin (FY, 2018), %

78.1%

Net income (FY, 2018)

5.5b

EBIT (FY, 2018)

8.2b

Market capitalization (22-Mar-2019)

81.3b

Closing stock price (22-Mar-2019)

63.8

Cash (31-Dec-2018)

17.9b

EV

88.0b
Gilead Sciences's current market capitalization is $81.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

11.2b24.9b32.6b30.4b26.1b22.1b

Revenue growth, %

122%31%(7%)

Cost of goods sold

2.9b3.8b4.0b4.3b4.4b4.9b

Gross profit

8.3b21.1b28.6b26.1b21.7b17.3b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018

Revenue

2.8b5.0b6.5b6.0b7.6b8.2b8.3b7.8b7.8b7.5b6.5b7.1b6.5b5.1b5.6b

Cost of goods sold

681.9m813.2m924.7m987.3m882.0m998.0m1.1b1.2b864.0m1.1b957.0m1.1b1.0b1.0b1.1b

Gross profit

2.1b4.2b5.6b5.1b6.7b7.2b7.2b6.6b6.9b6.4b5.5b6.0b5.5b4.1b4.5b

Gross profit Margin, %

75%84%86%84%88%88%87%85%89%85%85%84%84%80%81%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.1b10.0b12.9b8.2b7.6b17.9b

Inventories

2.1b1.4b2.0b1.6b801.0m814.0m

Current Assets

7.3b17.7b24.8b20.4b31.8b35.8b

PP&E

1.2b1.7b2.3b2.9b3.3b4.0b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018

Cash

2.0b6.4b8.7b6.2b10.6b7.4b14.0b6.3b6.5b9.8b10.3b8.7b11.5b7.6b14.6b

Accounts Receivable

2.0b3.2b3.4b2.9b4.8b5.3b6.1b

Inventories

1.9b2.1b2.1b1.9b1.9b2.0b2.0b1.9b1.9b1.9b1.5b1.4b1.1b885.0m816.0m

Current Assets

7.0b13.0b15.5b12.6b20.1b18.1b25.9b19.3b18.4b21.4b21.4b28.6b35.3b30.3b34.9b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

3.1b12.1b18.1b13.5b4.6b5.5b

Depreciation and Amortization

233.0m226.0m

Inventories

(343.1m)143.0m(855.0m)(488.0m)(253.0m)(310.0m)

Accounts Payable

(97.7m)(289.0m)226.0m47.0m(430.0m)(39.0m)
USDY, 2018

EV/EBIT

10.7 x

EV/CFO

10.5 x

EV/FCF

11.8 x

Revenue/Employee

2.2m

Financial Leverage

3 x
Show all financial metrics

Gilead Sciences Operating Metrics

FY, 2016

Countries

30

Phase I Trials Products

3

Phase II Trials Products

12

Phase III Trials Products

6
Show all operating metrics

Gilead Sciences Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Kite PharmaAugust 28, 2017$11.90 b

Gilead Sciences Revenue Breakdown

Embed Graph

Gilead Sciences revenue breakdown by geographic segment: 20.9% from Europe, 63.7% from United States, 8.3% from Japan and 7.1% from Other

Report incorrect company information

Gilead Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Gilead Sciences News and Updates

Global Human Immunodeficiency Virus (HIV) Drugs Market 2019-2025 with AbbVie, Merck, Gilead Sciences, Bristol-Myers Squibb, Janssen & GSK Dominating

DUBLIN, Feb. 20, 2019 /PRNewswire/ -- The "Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 - 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts" report has been added to ResearchAndMarkets.com's offering. The global human immunodeficiency virus (HIV) drugs market...

PhRMA Welcomes Genentech and Gilead Sciences to Association

WASHINGTON, Jan. 17, 2019 /PRNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Genentech, a member of the Roche Group, South San Francisco, and Gilead Sciences, Inc., Foster City, California joined the association as members. Genentech and...

Global Parkinsons Disease Drugs Market Is Likely to Witness Tremendous Growth by 2025: Key Players are Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma…

The Global Parkinsons Disease Drugs Market Report includes a comprehensive analysis of the present market. The report starts with the basic Parkinsons Disease Drugs Market overview and then goes into each and every detail. Posted via Industry Today. Follow us on Twitter @IndustryToday

Hepatitis C Market to witness astonishing growth (CAGR of 19.20) with Key Players F. Hoffmann-La Roche, Gilead Sciences, Johnson & Johnson

HTF analysts forecast the Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018. Posted via Industry Today. Follow us on Twitter @IndustryToday

Gilead Sciences to hire Roche executive O'Day as new CEO -source

Drugmaker Gilead Sciences Inc will name Roche Holding AG executive Daniel O'Day as its new chief executive officer, according to a source familiar with the matter.

The Wall Street Journal: Gilead Sciences plans to hire Roche executive Daniel O’Day as its next CEO

Gilead Sciences Inc. is planning to hire industry veteran Daniel O’Day to take the helm and help the drug company revive sales and recover from a disappointing deal, according to people familiar with the matter.
Show more
Report incorrect company information

Gilead Sciences Frequently Asked Questions

  • When was Gilead Sciences founded?

    Gilead Sciences was founded in 1987.

  • Who are Gilead Sciences key executives?

    Gilead Sciences's key executives are John F. Milligan, Gregg H. Alton and Andrew Dickinson.

  • How many employees does Gilead Sciences have?

    Gilead Sciences has 11,000 employees.

  • What is Gilead Sciences revenue?

    Latest Gilead Sciences annual revenue is $22.1 b.

  • What is Gilead Sciences revenue per employee?

    Latest Gilead Sciences revenue per employee is $2 m.

  • Who are Gilead Sciences competitors?

    Competitors of Gilead Sciences include Merck, CVS and Amgen.

  • Where is Gilead Sciences headquarters?

    Gilead Sciences headquarters is located at 333 Lakeside Dr, Foster City.

  • Where are Gilead Sciences offices?

    Gilead Sciences has offices in Foster City, Seattle, San Dimas, Oceanside and in 2 other locations.

  • How many offices does Gilead Sciences have?

    Gilead Sciences has 6 offices.